Posters

Iris implants and their complications: two case reports

Poster Details

First Author: M.Molero Senosiain SPAIN

Co Author(s):    L. Morales-Fernandez   L. Salazar Quiñones   C. Valor-Suarez   J. Martinez de la Casa   R. Cuiña Sardiña   J. Garcia-Feijoo     

Abstract Details

Purpose:

Surgical management of the complications that occur after the use of iris implants.

Setting:

Iris prostheses replace the morphology and function of healthy iris, generally to supply total or partial iridian defects. Alternatives have arisen for cosmetic purposes such as the NewColoriris implant (NewColorIris, Kahn, Medical Devices). Two clinical-cases are presented.

Methods:

Case1: 26-year-old man with bilateral secondary glaucoma. NewColorIris iris implant for cosmetic purposes in both eyes(BE) 5years earlier in Panama. It required the explant of prostheses, cataract surgery, new iridian implant, glaucoma surgeries in BE and DSAEK in left eye(LE). Visual acuity20/200  and intraocular pressure (IOP)40mmHg inBE. Faced with poor IOPcontrol, he got Ahmed valve in BE, good control after surgery. Case2:12-year-old poor IOP control. Trauma in LE 6months before (traumatic cataract, hemovitreous and aniridia). Underwent phacoemulsification with bag-lens, capsular-tension-ring, pars plana vitrectomy and iris implant in sulcus.  IOP40mmHg with maximum medical treatment requiring Ahmed-valve implant with good IOPcontrol.

Results:

The complications associated with Newcoloriris prostheses used in healthy eyes are difficult to manage and are accompanied by a low final visual acuity. On the other hand, there are other iridian prostheses whose use would be justified and the accompanying morbidity is associated with the underlying pathology.

Conclusions:

The complications associated with Newcoloriris prostheses used in healthy eyes are difficult to manage and are accompanied by a low final visual acuity. On the other hand, there are other iridian prostheses whose use would be justified and the accompanying morbidity is associated with the underlying pathology.

Financial Disclosure:

None